A first-in-human study of a next-generation CRISPR gene-editing therapy for sickle cell disease has reported encouraging early results. In the phase 1/2 trial, researchers said 80% of the first 25 treated patients achieved a durable response, suggesting the approach may offer meaningful relief for a disease that can cause severe pain, organ damage and repeated hospitalizations.

The findings, published on Friday, add to growing interest in gene-editing treatments that aim to address the root genetic cause of sickle cell disease rather than only managing symptoms. While the early response rate is notable, the trial is still small and remains in the early stages, meaning longer follow-up and larger studies will be needed to determine safety, durability and broader effectiveness.

Sickle cell disease affects millions of people worldwide, with a heavy burden on Black communities in the United States and populations across Africa, the Middle East and parts of South Asia. For many patients, even incremental progress in treatment can translate into fewer crises, less pain and a better quality of life.

Researchers and clinicians will now be watching whether the therapy’s early promise holds up as the study expands. If confirmed in larger trials, CRISPR-based treatments could mark a significant step forward in the fight against one of the world’s most painful inherited blood disorders.